Myriad RBM Announces the Launch of OncologyMAP® v. 2.0

Myriad RBM Announces the Launch of OncologyMAP® v. 2.0

Myriad Genetics (NASDAQ: MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has launched OncologyMAP® v. 2.0, a powerful research tool developed with funding and direction from the National Cancer Institute and the Cancer Prevention Research Institute of Texas. OncologyMAP® v. 2.0 is a comprehensive, cost-effective testing service that builds on the success of the original OncologyMAP® service by increasing the scope and diversity of biomarker analysis for drug re-tasking, indication expansion, and patient stratification studies and provides researchers with the ability to accelerate the pace of discovery, validation, and translation of cancer biomarkers into clinically useful tests......................

paywalled: US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology (breast/ovarian mutation)

US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology

US firm corners exclusive license for RAD51C cancer gene

Bryant Furlow

 

"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C , under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks.

“I think it is unfortunate for both the clinical and research communities”, Jim Evans (University"

press release: (OVA1) Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer

Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer


(press release) About OVA1
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125.(1) In addition, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment,(1) and it increased detection of malignancy over ACOG guidelines from 77% to 94%.(2) As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics.

media: AMP Optimistic in Suit to invalidate Patents on Breast Cancer Genes (BRCA/ovarian....)

Blogger's Note: typical reminder that the Myriad 'breast cancer' genetic testing is not only for breast cancer

AMP Optimistic in Suit to invalidate Patents on Breast Cancer Genes

Reuters: Myriad gene patent ruling sent back to lower court

 Reuters: Myriad gene patent ruling sent back to lower court

"The move is expected to delay a verdict in the Myriad case by as much as several years."

Supreme Court Ruling Creates Uncertainty for Diagnostics Companies - 03/23/2012 - The Burrill Report

Supreme Court Ruling Creates Uncertainty for Diagnostics Companies - 03/23/2012 - The Burrill Report

Myriad Genetics slips on patent concerns - BusinessWeek

Myriad Genetics slips on patent concerns - BusinessWeek

ImmunoCellular Therapeutics Licenses Novel Immunotherapeutic Target EphA2 from University of Pittsburgh - MarketWatch

ImmunoCellular Therapeutics Licenses Novel Immunotherapeutic Target EphA2 from University of Pittsburgh - MarketWatch

ImmunoCellular Therapeutics Licenses Novel Immunotherapeutic Target EphA2 from University of Pittsburgh

LOS ANGELES, Mar 22, 2012 (BUSINESS WIRE) -- ImmunoCellular Therapeutics IMUC +12.14% today announced that it has entered into an agreement with University of Pittsburgh (Pitt) under which Pitt has licensed to the Company intellectual property surrounding EphA2, a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies. This agreement grants a world-wide exclusive license to the Pitt intellectual property for ovarian and pancreatic cancers; and a world-wide non-exclusive license to the Pitt intellectual property for brain cancer. The financial terms of the agreement were not disclosed.

The Company will employ the Pitt intellectual property in the development and commercialization of ICT-140, a multivalent, dendritic cell-based vaccine for the treatment of ovarian cancer. ICT-140 is designed to target cancer stem cells as well as daughter cells in ovarian cancer by targeting multiple different antigens including EphA2, mesothelin, Her-2/neu, IL-13Ra2 and several other undisclosed antigens......

Mayo Clinic - Mayo Clinic Reacts to Unanimous Supreme Court Decision (patents/Prometheus/blood test)

Mayo Clinic - Mayo Clinic Reacts to Unanimous Supreme Court Decision

Mayo Clinic Reacts to Unanimous Supreme Court Decision

Tuesday, March 20, 2012

AUDIO ALERT: Additional audio resources are available on the Mayo Clinic News Blog.

ROCHESTER, Minn. — "Today, the United States Supreme Court issued a unanimous decision in favor of Mayo Collaborative Services in a case against Prometheus Laboratories, Inc., that dates back to 2004. John Noseworthy, M.D., president & CEO, Mayo Clinic, issued the following statement in reaction to the decision:
"We are extremely pleased with the U.S. Supreme Court's decision. Mayo Clinic chose to pursue this lengthy litigation process because we believed it was in the best interests of our patients. This decision concerns the value of delivering high quality patient care in a timely manner and at an affordable cost.
"Essentially, everything we do at Mayo Clinic is about the needs of the patient and that's what this is all about. This is about everyday interactions between doctors and their patients."
At issue was a blood test developed by Prometheus that helps doctors decide the proper dosage for a drug called thiopurine, which is used to treat gastrointestinal illnesses. Mayo purchased this test until 2004, when Mayo researchers created an improved test. Prometheus sued for patent infringement and to block Mayo's use of its own test.
The decision allows other U.S. labs to offer a similar test, which will result in lower health-care costs for patients."

Supreme court rules against Nestle unit (Prometheus Laboratories) on patent

Reuters: Supreme court rules against Nestle unit on patent

WASHINGTON | Tue Mar 20, 2012 10:32am EDT

(Reuters) - The Supreme Court ruled on Tuesday that Prometheus Laboratories could not patent a diagnostic method to observe changes in a patient's body to determine the best drug dosage for certain diseases, a decision that may affect the future of personalized medicine.......

Blogger: “And you’re ugly too” | genomeboy (genetic testing/patents, brca....)

“And you’re ugly too” | genomeboy

"All of this, of course, was precipitated by AMP v. USPTO (“The Myriad Case”), in which patients with family histories of breast cancer asserted that they have not been able to get confirmatory or “second opinion” testing because there is but a single, exclusive licensee of the patents on the most clinically important genes that predispose to hereditary breast and ovarian cancer, BRCA1 and BRCA2.

I attended the public hearing at the USPTO in Alexandria, VA on 16 February 2012.  I was so appalled by what I heard that I attended the second one in San Diego on 9 March 2012 and testified. I am still adding links to my testimony in order to submit it before public comment closes on 26 March 2012. Here is a brief excerpt on Myriad’s unwillingness to share its mutation data:................"

[Lancet Oncology News] US firm corners exclusive license for RAD51C cancer gene

[News] US firm corners exclusive license for RAD51C cancer gene:

"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C, under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks."

Patents on Genetic Data Raise Legal Questions on Rights to DNA - Bloomberg

Is Myriad’s Patent On Breast Cancer Genes Valid? | CT Health I-Team (some things you may not know)

Jan 2012 BRCA patent dispute may head to US Supreme Court : The Lancet

"The long-running dispute over patents for the BRCA1 and BRCA2 genes granted to Myriad Genetics may finally be laid to rest by the US Supreme Court....."

Year in Review: Gene Patent Case May Head to Supreme Court - Myriad + Mayo/Prometheus Labs

Gene Patent (Myriad) in Cancer Test Upheld by Appeals Panel - NYTimes.com (BRCA 1/2)

Genetics Company Myriad May Shift From Patents To Proprietary Data | Intellectual Property Watch

New Candidate Antibody-Drug Conjugate Gains Broad Patent Coverage - financial news (EGP-1 or TROP-2)

Court Backs Patents for Diagnostic Tests - NYTimes.com